CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.
Saved in:
| Title: | CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. |
|---|---|
| Authors: | Geyer MB; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY., DeWolf S; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY., Mi X; Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY., Weis K; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY., Shaffer BC; Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Cadzin B; Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY., McAvoy D; Immune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY., Katsamakis Z; Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Lorenc R; Pharmacology Program, Graduate School of Medical Sciences, Weill Cornell Medical College, New York, NY., Lewis AM; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY., Gipson B; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY., Cuibus MA; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY., Girotra NN; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY., Wu K; Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Smith N; Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Burns ER; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY., Um JS; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY., Yoo S; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY., Masouleh BK; Tigen Pharma, Lausanne, Switzerland., Galera P; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Hosszu K; Immune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY., Chaudhari J; Biotherapeutics Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY., Wang X; Biotherapeutics Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY., Lin Q; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.; Pharmacology Program, Graduate School of Medical Sciences, Weill Cornell Medical College, New York, NY., Curran KJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Park JH; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY., Scheinberg DA; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.; Pharmacology Program, Graduate School of Medical Sciences, Weill Cornell Medical College, New York, NY.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., van den Brink MRM; Hematologic Malignancies Program, City of Hope National Medical Center, Duarte, CA., Abdel-Wahab O; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.; Pharmacology Program, Graduate School of Medical Sciences, Weill Cornell Medical College, New York, NY., Brentjens RJ; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Daniyan AF; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY. |
| Source: | Blood [Blood] 2025 Dec 25; Vol. 146 (26), pp. 3163-3174. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
